July 21, 2011 7:10 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Piper Jaffray provided color on Edwards Lifesciences (NYSE: EW). In a research report published today, the rating agency commented on FDA's favorable response to the company's new product.In the report, Piper Jaffray states, “The FDA held an advisory panel meeting for EW's Sapien® valve on Wednesday.As expected, the overall view from FDA and a majority of the panelists wasfavorable, despite considerable discussion on the higher stroke rates experiencedwith the device. We continue to believe Sapien® will be approved on time or earlyin the US, and that the Company's goal of $25M in US sales by year end will bemet or exceeded.”At the moment, Piper Jaffray has an Overweight rating and a price target of $94 placed on the company's stock. On Wednesday, EW lost 2.36% of its value to end the day at $87.53.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.